Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2007-06-15

• Fields of study

  Medicine, Psychology

• Identifiers
  PMID 17650055
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.

  2007cited by this paper
• Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review.

  2007cited by this paper
• Switching antipsychotics: an updated review with a focus on quetiapine

  2006cited by this paper
• Acute Dystonia with Low-Dosage Aripiprazole in Tourette's Disorder

  2006cited by this paper
• Beyond psychopharmacology. Psychosocial strategies for getting the best results when switching antipsychotic medications.

  2006cited by this paper
• Treatment of cardiac risk factors among patients with schizophrenia and diabetes.

  2006cited by this paper
• Switching in the era of atypical antipsychotics. An updated review.

  2006influential reference
• Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.

  2005cited by this paper
• Second-Generation (Atypical) Antipsychotics and Metabolic Effects

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005influential reference
• Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.

  2005cited by this paper
• Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study.

  2004cited by this paper
• Modafinil and antipsychotic-induced sedation.

  2004cited by this paper
• Physical health monitoring of patients with schizophrenia.

  2004cited by this paper
• Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.

  2004cited by this paper
• Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report.

  2004cited by this paper
• Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia.

  2004cited by this paper
• Safety and Tolerability: How Do Newer Generation “Atypical” Antipsychotics Compare?

  2004cited by this paper
• Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia.

  2004cited by this paper
• Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

  2003cited by this paper
• Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

  2003cited by this paper
• Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.

  2002cited by this paper
• The effects of novel antipsychotics on glucose and lipid levels.

  2002cited by this paper
• Switch to quetiapine in antipsychotic agent-related hyperprolactinemia

  2002cited by this paper
• Novel Antipsychotics and Severe Hyperlipidemia

  2000cited by this paper
• Olanzapine increases weight and serum triglyceride levels.

  1999cited by this paper
• Clozapine–olanzapine: a potentially dangerous switch. A report of two cases

  1999cited by this paper
• Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.

  1999cited by this paper
• Risperidone (Risperdal): clinical experience with a new antipsychosis drug.

  1999cited by this paper
• Long-term considerations after switching antipsychotics.

  1998cited by this paper
• A comparison of patients' and prescribers' beliefs about neuroleptic side‐effects: prevalence, distress and causation

  1998cited by this paper
• Switching antipsychotic medications.

  1997cited by this paper
• Practice guideline for the treatment of patients with schizophrenia

  1997influential reference
• Switching between Clozapine and Risperidone Treatment

  1997cited by this paper
• Atypical antipsychotic drugs and long-term outcome in schizophrenia.

  1996cited by this paper
• Neuroleptic withdrawal in schizophrenic patients. A review of the literature.

  1995cited by this paper
• Tardive Dyskinesia

  1992cited by this paper

• Engagement, Disengagement and Re‐Engagement in Mental Health Services Among Young Patients With First‐Episode Psychosis: A Scoping Review

  2025cites this paper
• Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report.

  2025cites this paper
• Oral versus long-acting injectable antipsychotics in schizophrenia spectrum disorders: A systematic review of patients' subjective experiences.

  2025cites this paper
• Antipsychotic medications associated with increased length of hospital stay in autoimmune encephalitis and multiple sclerosis: A retrospective study.

  2024cites this paper
• Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: A systematic review.

  2024cites this paper
• Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia

  2021cites this paper
• Prévention et prise en charge du diabète de type 2 chez les patients souffrant de schizophrénie traités par antipsychotiques de seconde génération

  2020cites this paper
• Psychoeducation and motivational interviewing to reduce relapses and increase patients’ involvement in antipsychotic treatment: interventional study

  2020cites this paper
• Understanding the multidimensional phenomenon of medication adherence attitudes in psychosis.

  2020cites this paper
• Predictive factors of functional remission in patients with early to mid-stage schizophrenia treated by long acting antipsychotics and the specific role of clinical remission.

  2019cites this paper
• Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5‐HT2A receptors in rats

  2019cites this paper
• Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program

  2017cites this paper
• Treatment Duration With Long-Acting Injectable Antipsychotics After In-hospital Initiation: A Retrospective Cohort Study

  2017cites this paper
• When all else fails: supervised treatment in outpatient for schizophrenia (STOPS)

  2017cites this paper
• Redefining Medication Adherence in the Treatment of Schizophrenia: How Current Approaches to Adherence Lead to Misinformation and Threaten Therapeutic Relationships.

  2016cites this paper
• Impact of Psychoeducation on Knowledge of and Attitude Toward Medications in Clients With Schizophrenia and Schizoaffective Disorders.

  2016cites this paper
• The Use of Long-Acting Injectable Antipsychotics in Schizophrenia : Evaluating the Evidence Part 1 : Efficacy and Safety of LAIs � � �

  2016cites this paper
• Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists

  2016cites this paper
• The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.

  2016cites this paper
• Mental health service utilisation after a Community Treatment Order: A comparison between three modes of termination

  2016cites this paper
• A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders.

  2015cites this paper
• Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study

  2015cites this paper
• Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders

  2015cites this paper
• effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study

  2015cites this paper
• Recommendations for switching antipsychotics . A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry

  2015cites this paper
• Adhärenz in der Psychopharmakologie

  2015cites this paper
• Partial and non‐adherence: we need all the help we can get

  2015cites this paper
• Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists

  2015influential citation
• Consumers’ questions about antipsychotic medication: revealing safety concerns and the silent voices of young men

  2015cites this paper
• [Computer-assisted treatment pathway for schizophrenia. Development and initial experiences].

  2015cites this paper
• Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence

  2015cites this paper
• Pharmakologische Langzeitbehandlung schizophrener Erkrankungen

  2014cites this paper
• EDV-gestützter Behandlungspfad für Schizophrenie

  2014cites this paper
• Long-Term Pharmacological Management of Schizophrenia

  2014cites this paper
• Schizophrenia--time to commit to policy change.

  2014cites this paper
• SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects

  2014cites this paper
• The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

  2014cites this paper
• Aumento de peso y de índice de masa corporal en niños y adolescentes tratados con antipsicóticos: revisión crítica y estudio longitudinal

  2014influential citation
• Implementation of a Weight Loss Program for Latino Outpatients with Severe Mental Illness

  2013cites this paper
• Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study

  2013cites this paper
• Effectiveness of sulpiride in adult patients with schizophrenia.

  2013cites this paper
• Schizophrenia and antipsychotic medication--better adherence, better outcomes?

  2013cites this paper
• New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia

  2013cites this paper
• Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences

  2013cites this paper
• Adherence: The Great Masquerader of Treatment-Resistance

  2013cites this paper
• Characteristics Associated With the Continuity of Atypical Antipsychotic Treatment Among Youth Discharged From Residential Treatment

  2013cites this paper
• Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review

  2013cites this paper
• Antipsychotics switching strategies in real life . A longitudinal study in clinical practice

  2012cites this paper
• Iloperidone for the treatment of schizophrenia: an updated clinical review.

  2012cites this paper
• Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia.

  2012cites this paper
• Pharmacological treatment of schizophrenia

  2012cites this paper
• Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: A prospective naturalistic study

  2012cites this paper
• Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study

  2012cites this paper
• Classical Somatic Treatments: Pharmacotherapy and ECT

  2012cites this paper
• Measurement of waist circumference at different sites affects the detection of abdominal obesity and metabolic syndrome among psychiatric patients.

  2012cites this paper
• PRINCIPLES AND PRACTICES OF MEDICATION MANAGEMENT FOR PEOPLE WITH SCHIZOPHRENIA Evolution within a Recovery-Based Framework of Care

  2012cites this paper
• Antipsychotics switching strategies in real life: A longitudinal study in clinical practice

  2012cites this paper
• Perceptions of relapse risks following first‐episode psychosis and attitudes towards maintenance medication: a comparison between nursing and social work professionals

  2011cites this paper
• Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients

  2011cites this paper
• The Adherence Interview: Better Information, Better Alliance

  2011cites this paper
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

  2011cites this paper
• Environmental and genetic modulation of dopaminergic development

  2011cites this paper
• Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry.

  2011cites this paper
• Novelty seeking and medication adherence in patients with schizophrenia.

  2011cites this paper
• Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.

  2011cites this paper
• Long-acting injectable antipsychotics and the management of nonadherence

  2011cites this paper
• Principles of Pharmacological Treatment in Schizophrenia

  2011cites this paper
• Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone

  2011cites this paper
• Medication adherence in schizophrenia

  2011cites this paper
• Withdrawal related adverse effects of antipsychotic medication in a patient with first-episode schizophrenia

  2011cites this paper
• Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry

  2011cites this paper
• Metformin for Atypical Antipsychotic-Induced Weight Gain and Glucose Metabolism Dysregulation

  2010cites this paper
• Antipsychotic dosing: how much but also how often?

  2010cites this paper
• The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country

  2010cites this paper
• Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia

  2010cites this paper
• Crosswalking public health and health education competencies: implications for professional preparation and practice.

  2010cites this paper
• Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature

  2010cites this paper
• Epidemiology-driven neurodevelopmental animal models of schizophrenia.

  2010cites this paper
• Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).

  2010cites this paper
• Methodological challenges in psychiatric treatment adherence research.

  2010cites this paper
• Comment évaluer la qualité de l’observance ?☆

  2009cites this paper
• ALTERACIONES METABOLICAS ASOCIADAS AL USO DE TERAPIA ANTIPSICOTICA

  2009cites this paper
• Implicit versus explicit attitudes toward psychiatric medication: Implications for insight and treatment adherence.

  2009cites this paper
• Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases

  2009cites this paper
• Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.

  2009cites this paper
• Medication Adherence: A Review of the Literature and Implications for Clinical Practice

  2009cites this paper
• The risks and benefits of switching antipsychotics: a case study approach.

  2009cites this paper
• Improved Body Weight and Metabolic Outcomes in Overweight or Obese Psychiatric Patients Switched to Amisulpride From Other Atypical Antipsychotics

  2009cites this paper
• NMR Metabolomics Techniques and Mathematical Tools as an Aid in Neurological Diagnosis

  2009cites this paper
• Eitim Kurumlar› D›fl›nda Görevli Bir Grup Psikiyatristin Antipsikotik Seçme, Kombine Etme ve Doz Ayarlama Örüntüleri

  2009cites this paper
• Switching of antipsychotics to aripiprazole in the treatment of schizophrenia.

  2009cites this paper
• Atypical antipsychotic induced weight gain and metabolic disorders

  2009cites this paper
• eview linical monitoring and management of the metabolic yndrome in patients receiving atypical antipsychotic edications

  2008cites this paper
• Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics

  2008cites this paper
• Clinical decision making in the treatment of mania.

  2008cites this paper
• Ziprasidone for the Treatment of Acute Manic or Mixed Episodes Associated with Bipolar Disorder

  2007cites this paper
• A roadmap to key pharmacologic principles in using antipsychotics.

  2007cites this paper
• effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study

  year unknowncites this paper